Evidence map›Paper›PMID 38182656›Full record

ArticleEye (London, England)2024

Mid-term real world outcomes of the Hydrus

David Kiramira, Urs Voßmerbäumer, Norbert Pfeiffer, Lea K M Linnerth-Braun, Katrin Lorenz, Verena Prokosch

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Eye (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. HydrusJournal of clinical medicine · 2026
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

David KiramiraDepartment of Ophthalmology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.
Urs VoßmerbäumerDepartment of Ophthalmology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.
Norbert PfeifferDepartment of Ophthalmology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.ORCID http://orcid.org/0000-0002-5766-2617
Lea K M Linnerth-BraunDepartment of Periodontology and Operative Dentistry, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.
Katrin Lorenz *Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany.
Verena Prokosch *Department of Ophthalmology, University Medical Center, Johannes Gutenberg-University, Mainz, Germany. vprokosch@gmx.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the mid-term clinical results and the safety aspects of the Hydrus

designRetrospective case series.

methodsHydrus

main outcome measuresThe primary endpoint was reduction in IOP compared to baseline. Target IOP levels were set at ≤20 mmHg, ≤18 mmHg and ≤15 mmHg. Kaplan-Meier survival was defined as a reduction in IOP of ≥20% compared to baseline. Secondary endpoints were reduction in number of glaucoma medications and safety assessments addressing visual acuity, adverse events, re-surgery rate and identification of factors that made the implantation more difficult.

result101 eyes underwent Hydrus

conclusionThis study underlines the effectiveness and the safety of the Hydrus

Indexed as

Glaucoma Drainage ImplantsGlaucoma, Open-AngleIntraocular PressureStentsVisual AcuityAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedProsthesis ImplantationRetrospective StudiesTonometry, OcularTreatment Outcome

Identifiers

PMID38182656
PMCPMC11126590

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.